Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential

Catalysts

About RxSight

RxSight develops and sells the Light Adjustable Lens and Light Delivery Device system for cataract patients seeking customized visual outcomes.

What are the underlying business or industry changes driving this perspective?

• The company is leaning heavily on premium cataract procedures at the higher end of the market, so any slowdown in this patient group or shift toward lower cost options could limit Light Adjustable Lens revenue growth and cap the benefit of a larger LDD installed base on overall revenue.
• Management is deliberately pulling back on LDD placements after building an installed base of 1,109 units. This may reduce new account openings and constrain the funnel of future LAL users, pressuring top line growth and keeping earnings under strain.
• International expansion in Europe and Asia depends on regulatory progress, key opinion leader adoption and local data. If these rollouts take longer or scale more slowly than planned, the contribution to revenue and margin leverage from outside the U.S. could stay limited.
• Rising operating expenses, including SG&A in the US$145 million to US$155 million range and stock based compensation of US$30 million to US$32 million, risk outpacing revenue from premium procedures. This could delay any path toward net income breakeven and keep net margins under pressure.
• The company continues to operate with GAAP net losses. If utilization per LDD and LAL procedure volumes do not improve meaningfully relative to this cost structure, losses could persist and weigh on future earnings and cash generation despite the current US$227.5 million cash and investments balance.

Assumptions

This narrative explores a more pessimistic perspective on RxSight compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming RxSight's revenue will grow by 3.2% annually over the next 3 years.
• The bearish analysts are not forecasting that RxSight will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate RxSight's profit margin will increase from -25.1% to the average US Medical Equipment industry of 12.9% in 3 years.
• If RxSight's profit margin were to converge on the industry average, you could expect earnings to reach $20.2 million (and earnings per share of $0.47) by about January 2029, up from $-35.7 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 21.4x on those 2029 earnings, up from -11.5x today. This future PE is lower than the current PE for the US Medical Equipment industry at 30.7x.
• The bearish analysts expect the number of shares outstanding to grow by 1.55% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.73%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The installed base of 1,109 LDDs and more than 2,000 surgeons already implanting LALs gives RxSight a large footprint to work with. If the new training programs such as MasterClass and Elevate keep lifting LAL utilization, revenue from procedures could trend higher than expected and support improved earnings and net margins over time.
• Premium IOLs still account for a relatively small share of the overall cataract market, and RxSight currently sits at about 10% share within premium IOLs. If long term adoption of premium options accelerates, especially as practices respond to lower Medicare fees by leaning into premium offerings, LAL volumes and revenue could rise faster than a bearish view assumes.
• International markets account for roughly two thirds of premium procedures, and RxSight is already moving into Europe, Asia and Canada with a dedicated EVP of International. If global KOL support and local data translate into growing case volumes, the additional scale could support higher revenue, better gross margins and eventually narrower net losses.
• Third quarter gross margin of 79.9% with guidance for 76% to 77% for 2025 suggests the business model benefits from a richer LAL mix and lower unit costs. If this high margin profile proves durable as volumes build, gross profit and the path toward earnings improvement could be stronger than a sustained loss scenario implies.
• RxSight reported a GAAP net loss of $9.8 million in the third quarter of 2025 but also held US$227.5 million of cash equivalents and short term investments and posted a much smaller non GAAP loss of $1.7 million. If operating expenses grow more slowly than revenue and the company continues to benefit from existing cash, the impact of losses on future earnings and financial flexibility could be less severe than bears expect.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for RxSight is $8.0, which represents up to two standard deviations below the consensus price target of $10.33. This valuation is based on what can be assumed as the expectations of RxSight's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $156.2 million, earnings will come to $20.2 million, and it would be trading on a PE ratio of 21.4x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $9.99, the analyst price target of $8.0 is 24.9% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.